temporarily

WASHINGTON — The Supreme Court is leaving access to a widely used abortion pill untouched until at least Thursday, while the justices consider whether to allow restrictions on the drug, mifepristone, to take effect.

Justice Samuel A. Alito Jr.’s order Monday allows women seeking abortions to continue obtaining the pill at pharmacies or through the mail, without an in-person visit to a doctor. It prevents restrictions on mifepristone imposed by a federal appeals court from taking effect for the time being.

The court is dealing with its latest abortion controversy four years after its conservative majority overturned Roe vs. Wade and allowed more than a dozen states to effectively ban abortion outright.

The case before the court stems from a lawsuit Louisiana filed to roll back the Food and Drug Administration’s rules on how mifepristone can be prescribed. The state claims the policy undermines the ban there, and it questions the safety of the drug, which was first approved in 2000 and has repeatedly been deemed safe and effective by FDA scientists.

Lower courts concluded that Louisiana is likely to prevail, and a three-judge panel of the U.S. 5th Circuit Court of Appeals ruled that mail access and telehealth visits should be suspended while the case plays out.

The drug is most often used for abortion in combination with another drug, misoprostol. Medication abortions accounted for nearly two-thirds of all abortions in the U.S. in 2023, the last year for which statistics are available.

The current dispute is similar to one that reached the court three years ago.

Lower courts then also sought to restrict access to mifepristone, in a case brought by physicians who oppose abortion. They filed suit in the months after the court overturned Roe.

The Supreme Court blocked the 5th Circuit ruling from taking effect over the dissenting votes of Alito and Justice Clarence Thomas. Then, in 2024, the high court unanimously dismissed the doctors’ suit, reasoning they did not have the legal right, or standing, to sue.

In the current dispute, mainstream medical groups, the pharmaceutical industry and Democratic members of Congress have weighed in cautioning the court against limiting access to the drug. Pharmaceutical companies said a ruling for abortion opponents would upend the drug approval process.

The FDA has eased a number of restrictions initially placed on the drug, including who can prescribe it, how it is dispensed and what kinds of safety complications must be reported.

Despite those determinations, abortion opponents have been challenging the safety of mifepristone for more than 25 years. They have filed a series of petitions and lawsuits against the agency, generally alleging that it violated federal law by overlooking safety issues with the pill.

President Trump’s administration has been unusually quiet at the Supreme Court. It declined to file a written brief recommending what the court should do, even though federal regulations are at issue.

The case puts Trump’s Republican administration in a difficult place. Trump has relied on the political support of antiabortion groups but has also seen ballot question and poll results that show Americans generally support abortion rights.

Both sides took the silence as an implicit endorsement of the appellate ruling. Alito is both the justice in charge of handling emergency appeals from Louisiana and the author of the 2022 decision that declared abortion is not a constitutional right and returned the issue to the states.

Sherman, Mulvihill and Perrone write for the Associated Press. Mulvihill reported from Haddonfield, N.J.

The United States Supreme Court has temporarily reinstated a rule allowing an abortion pill to be prescribed through telemedicine and dispensed through the mail, lifting a judicial ban that narrowed access to the medication nationwide.

Justice Samuel Alito issued an interim order on Monday, pausing for one week a decision by the New Orleans-based 5th US Circuit Court of Appeals to reimpose an older federal rule requiring an in-person clinician visit to receive mifepristone.

The 5th Circuit acted in a challenge to the rule by the Republican-led state of Louisiana.

The Supreme Court’s action, called an “administrative stay”, gives the justices more time to review emergency requests by two manufacturers of mifepristone to ensure that the drug can be provided via telehealth and the mail while the legal challenge plays out.

Alito ordered Louisiana to respond to the drugmakers’ requests by Thursday and indicated that the administrative stay would expire on May 11. The court would be expected to extend the interim stay or formally decide the requests by that time.

Alito, one of the nine-member court’s six conservative justices, acted because he is designated by the court to oversee emergency matters that arise in a group of states that includes Louisiana.

The case puts the contentious issue of abortion back in front of the justices, who must confront another effort by abortion opponents to scale back access to mifepristone, with the November US congressional elections looming.

The court in 2024 unanimously rejected an initial bid by anti-abortion groups and doctors to roll back Food and Drug Administration (FDA) regulations that had eased access to the drug, ruling that these plaintiffs lacked the necessary legal standing to pursue the challenge.

Mifepristone, given FDA regulatory approval in 2000, is taken with another drug called misoprostol to perform medication abortions, a method that now accounts for more than 60 percent of all abortions in the US.

The ongoing battles over abortion rights follow the court’s 2022 ruling that overturned its 1973 Roe v Wade precedent that had legalised abortion nationwide.

That ruling has prompted 13 states to enact near-total bans on the procedure, while several others have sharply restricted access.

Louisiana sued the FDA last year, claiming that a rule adopted during the administration of former US President Joe Biden, a Democrat – a rule that eased access to mifepristone by eliminating the in-person dispensing requirement – is illegal and undermines the state’s abortion ban.

The pill’s manufacturer, Danco Laboratories, and GenBioPro, which makes a generic version, intervened in the litigation to defend the 2023 regulation. The administration of current US President Donald Trump, a Republican, cited an ongoing review of safety regulations concerning mifepristone and opposed the state’s challenge.

In April, US Judge David Joseph in Lafayette, Louisiana, declined to block the regulation but agreed with the administration to put the case on hold pending the review. The 5th Circuit blocked the rule on May 1.

The legal and political fight over access to mifepristone has dominated the debate over abortion in the US over the past few years.

The American Civil Liberties Union (ACLU) called the top court’s decision on Monday a “positive short-term development”.

“The Supreme Court needs to put an end to this baseless attack on our reproductive freedom, once and for all,” Julia Kaye, senior lawyer for the Reproductive Freedom Project of the ACLU, said in a statement.

Since the Supreme Court revoked the right to abortion in 2022, Democrats have been seizing on the unpopularity of bans on the procedure and emphasising the issue in their electoral platforms.

Chuck Schumer, the top Democrat in the Senate, welcomed the top court’s decision on Monday, but said, “This fight is just beginning.”

“We will stop at nothing to prevent the Republicans from putting a national abortion ban into effect,” Schumer wrote on X.

On Monday, Republican Senator Josh Hawley cited disputed findings on the health risks associated with mifepristone, urging lawmakers to act.

“Now it’s time for Congress to ban it completely for use in abortion,” he said in a social media post.

May 2 (UPI) — A Texas judge on Friday temporarily paused the state’s ban on smokable hemp products, such as flower and joints, after three industry groups and multiple companies based in the state sued over it.

The state in March expanded its limit on THC in hemp products from 0.3% levels of Delta-9 THC to cover any form of THC beyond the state’s previous limit of 0.3% total THC in dry weight of the intoxicating group of chemicals.

This variety of chemicals includes Delta-8, various forms of Delta-9, and all other cannabinoids, with the exception of CBD and CBG.

The rule adopted by the state’s health department effectively banned all smokable forms of hemp because vapes and e-cigarettes that contain any form of cannabinoid were banned in Texas last September, the Texas State Law Library reported.

Since the federal government fully legalized hemp with low levels of Delta-9 THC, companies have produced hemp with boosted levels of other cannabinoids, including THCA, a non-psychoactive chemical that converts to Delta-9 THC when heated.

The groups that used the state contend that the health department overstepped their constitutional authority and that the new rules have done irreparable harm to the Texas hemp industry, CBS Austin reported.

“We are obviously excited about this ruling,” said Jason Snell, one of the attorneys that represents the industry groups and companies, KUT News reported.

“[The judge] issued a statewide injunction which prohibits what we believe are illegal rules from going into effect, which would cripple the hemp industry statewide and deprive consumers and every day Texans from access to legal products,” Snell said.

The Texas legislature last May passed a bill that would have effectively banned all of the products, but Texas Gov. Greg Abbot vetoed, which led the health department attempting to ban the products itself.

A previous temporary restraining order on the rule was set to expire Friday afternoon at 5 p.m., but the ruling — which covers all consumable hemp products — will now allow the industry to keep doing business.

, wit

Published on 30/04/2026 – 10:17 GMT+2•Updated
10:28

Brent crude, the international standard for oil prices, jumped by over 7% during early trading on Thursday, touching $126 per barrel, the highest intraday level since 2022 when Russia initiated the full-scale invasion of Ukraine.

ADVERTISEMENT

ADVERTISEMENT

The US benchmark crude, WTI, also rose more than 3% and hit over $110 per barrel.

At the time of writing, prices have corrected slightly with the front month contract for Brent trading at around $122 per barrel and WTI at roughly $108.5.

Prices are now the highest they have been since the start of the Iran war.

The surge in oil prices is a direct consequence of stalled negotiations over the reopening of the Strait of Hormuz, the absence of a clear path toward ending the war and a seemingly increased chance of US-Israeli military action returning.

US President Donald Trump is set to meet with the head of the US Central Command, Admiral Brad Cooper, on Thursday and receive a briefing on new military options for action in Iran, according to Axios which cites two unnamed people.

The meeting signals the potential for fresh escalation in the Middle East as the resumption of combat operations is reportedly “seriously under consideration” and oil markets have reacted swiftly to the news.

A ceasefire has held since early April but recent negotiating efforts have fallen flat with the two sides refusing to meet. Meanwhile, the US and Iran both maintain their blockade of the vital Strait of Hormuz.

US Central Command has also reportedly asked for hypersonic missiles to be sent to the Middle East, which would mark the first time the US army has deployed that type of weapon.

The persistent blockade of ports and the threat of expanded combat have fundamentally reshaped market expectations.

A shifting landscape for OPEC and global supply

The spike in prices is occurring against a backdrop of significant structural change within the global oil hierarchy.

Earlier this week, the United Arab Emirates officially withdrew from the Organisation of the Petroleum Exporting Countries (OPEC) and its wider alliance (OPEC+), a move the nation claimed was necessary to prioritise its own national interests.

Under normal market conditions, the exit of a major producer from the cartel might be expected to signal a potential increase in supply or a decrease in price stability.

However, the sheer scale of the Iran war has rendered the UAE’s departure secondary in the minds of traders.

Despite the UAE’s exit, which was expected to potentially weaken OPEC’s grip on production quotas, prices have continued their upward trajectory.

This suggests that the “war premium” currently dominates all other market fundamentals.

Investors are currently less concerned with the internal politics of oil-producing nations and more focused on the immediate physical absence of Iranian crude, suspended shipping routes through the Strait of Hormuz and the threat to regional infrastructure.

However, the transition of the UAE to an independent actor still highlights a growing fragmentation in global energy governance at a time when the world’s energy security is at its most vulnerable.

Government says it will run the administrative functions of Sri Lanka Cricket until reforms are implemented.

Sri Lanka’s government has taken control of the country’s cricket board, saying it is a temporary measure designed to pave the way for “structural reforms”.

“All administrative functions of Sri Lanka Cricket (SLC) will be temporarily brought under the Ministry of Youth Affairs and Sports, effective today,” the ministry said on Wednesday.

A committee will be appointed shortly “to address the current issues in cricket and implement structural reforms”, it added.

SLC is the country’s wealthiest sporting body but has been plagued by allegations of corruption and mismanagement.

The world governing body, the International Cricket Council, suspended Sri Lanka for two months in 2023-2024, citing political interference in the running of the national board.

Four-time SLC President Shammi Silva resigned on Tuesday, along with his entire committee, after the government intervened.

Sri Lanka made an early exit from the T20 World Cup, which it cohosted with India in February-March.